#Stribild

That’s compared with HIV-negative men.

Two men claim they developed bone and kidney problems after taking TDF. A related class action lawsuit has also been filed.

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.

Clinicians have presented a pair of case reports of patients going on the HIV medication and experiencing severe mental health reactions.

People with HIV taking Viread, especially if combined with Norvir, should receive regular kidney monitoring.

Increases may be designed to push patients to the company’s newer regimens.

Lawsuit: Gilead has manipulated the patent system to extend its control (and profit) of tenofovir, found in many HIV regimens.

Long-term Viread (tenofovir disoproxil fumarate, or TDF) use is linked with a raised risk of end-stage liver cancer in HIV-positive people.

The FDA has approved Gilead’s single-tablet antiretroviral regimen Genvoya, the first HIV treatment to include a new version of tenofovir.

A comparison between the single-tablet HIV med Stribild with a new version of the tablet that includes a revised form of tenofovir has...

Medications used to boost the levels of other HIV antiretrovirals are the most likely out of all ARVs to have dangerous interactions with...

An updated version of Viread (tenofovir) offers slightly better viral suppression and improves indicators of kidney and bone health...

Gilead Sciences has applied to the FDA for approval of yet another combination HIV tablet including an updated version of tenofovir.

We now have four single tablet regimens.